RT Journal Article
T1 In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study.
A1 Quindos, Guillermo
A1 Miranda-Cadena, Katherine
A1 San-Millan, Rosario
A1 Borroto-Esoda, Katyna
A1 Canton, Emilia
A1 Linares-Sicilia, Maria Jose
A1 Hamprecht, Axel
A1 Montesinos, Isabel
A1 Tortorano, Anna Maria
A1 Prigitano, Anna
A1 Vidal-Garcia, Matxalen
A1 Marcos-Arias, Cristina
A1 Guridi, Andrea
A1 Sanchez-Reus, Ferran
A1 Machuca-Barcena, Jesus
A1 Rodriguez-Iglesias, Manuel Antonio
A1 Martin-Mazuelos, Estrella
A1 Castro-Mendez, Carmen
A1 Lopez-Soria, Leyre
A1 Ruiz-Gaitan, Alba
A1 Fernandez-Rivero, Marcelo
A1 Lorenzo, Damaris
A1 Capilla, Javier
A1 Rezusta, Antonio
A1 Peman, Javier
A1 Guarro, Josep
A1 Pereira, Joana
A1 Pais, Celia
A1 Romeo, Orazio
A1 Ezpeleta, Guillermo
A1 Jauregizar, Nerea
A1 Angulo, David
A1 Eraso, Elena
K1 Candida
K1 EUCAST
K1 SCY-078
K1 Antifungal resistance
K1 Antifungal testing
K1 Caspofungin
K1 Ibrexafungerp
K1 Micafungin
AB Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. The aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. Ibrexafungerp MICs ranged from 0.016 to ≥8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06-≥8 mg/L). Modal MICs/MIC50s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. Ibrexafungerp showed a potent in vitro activity against Candida.
PB Frontiers Research Foundation
YR 2022
FD 2022-04-19
LK http://hdl.handle.net/10668/20540
UL http://hdl.handle.net/10668/20540
LA en
NO Quindós G, Miranda-Cadena K, San-Millán R, Borroto-Esoda K, Cantón E, Linares-Sicilia MJ, et al. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Front Cell Infect Microbiol. 2022 May 16;12:906563
DS RISalud
RD Apr 12, 2025